Notice of Annual General Meeting of SenzaGen AB (publ)
The shareholders in SenzaGen AB (Publ.), Org. nr 556821–9207, ("Company") is hereby summoned to the Annual General Meeting held on Wednesday of the 15 May 2019 at 16.00 in Arrhenius at Medicon Village, building 401, Scheelevägen 2 in Lund.
Right to attend the general meeting and notification
Shareholders who wish to attend the Annual General Meeting must be included in the share register maintained by Euroclear Sweden AB as of Thursday of the 9 May 2019.
Shareholders shall also notify the Company of their participation and any assistants (no more than two) in the Annual General Meeting no later than Thursday of the 9 May 2019 The notification shall be in writing to SenzaGen AB, Medicon Village, 401, 223 81 Lund or by e-mail to anmalan@senzagen.com. The notification should state the name, personal/corporate identity number, shareholding, address and telephone number and, when applicable, information about representatives, counsels and assistants. When applicable, complete authorization documents, such as registration certificates and powers of attorney for representatives and assistants, should be appended the notification.
Nominee-registered shares
Shareholders, whose shares are registered in the name of a bank or other nominee, must temporarily register their shares in their own name with Euroclear Sweden AB in order to be entitled to participate in the Annual General Meeting. Such registration, which normally is processed in a few days, must be completed no later than Thursday of the 9 May 2019 and must therefore be requested from the nominee well before this date.
The complete notice is available via the link below.
For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com | Telephone: +46 768 284822
Tina Dackemark Lawesson, Director Investor Relations & Corporate Communications
Email: tina.lawesson@senzagen.com | Telephone: +46 708 202944
About GARD®
GARD® consists of a group of tests for analyzing chemicals' ability to start an allergic reaction in humans. By analyzing hundreds of markers, GARD® generates large amounts of data and delivers results with over 90 percent accuracy. This can be compared to today's standard method – tests on mice – which only achieves 70-75 percent precision. SenzaGen's test can also quantify the allergenic potential of a chemical substance.
About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the USA.
SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.senzagen.com.
